Rxrx stock forecast.
The average price target for Recursion Pharmaceuticals is $16.60. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst …
Nov 9, 2023 · Recursion Pharmaceuticals Inc Cl A (RXRX) $7.05 0.38 (5.70%) 16:00 EST RXRX Stock Quote Delayed 30 Minutes. Gil Blum, an analyst from Needham, reiterated the Buy rating on Recursion Pharmaceuticals (RXRX – Research Report). The associated price target is $15.00. Gil Blum’s Buy rating for Recursion ...Dec 1, 2023 · Company Summary. Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data ... Nowadays finding high-quality stock photos for personal or commercial use is very simple. You just need to search the photo using a few descriptive words and let Google do the rest of the work.
The average one-year price target for Recursion Pharmaceuticals Inc - ( NASDAQ:RXRX) has been revised to 17.17 / share. This is an increase of 7.12% from the prior estimate of 16.03 dated August ...Find the latest news headlines from Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.
GE stock has seen extremely strong gains of 85% from levels of $65 in early January 2021 to around $120 now, vs. an increase of about 20% for the S&P 500 over …According to our current RXRX stock forecast, the value of Recursion Pharmaceuticals, Inc. shares will drop by -9.72% and reach $ 6.59 per share by December 5, 2023. …
Before the stock market opened, RXRX stock had catapulted more than 130%. Nvidia stock rose 3.5% to 439.02. Recursion has a searchable data set spanning biology and chemistry. The company says its ...Average. $15.57. Current Price. $7.39. Options. Overview. Research & Ratings. Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume ... U.S. crude futures finish 1.2% higher $75.75 a barrel, the highest closing price since April 28, while Brent crude finishes above $80 for the first time since April 25, ending at $80.11. "Crude ...Recursion Pharmaceuticals Inc. 7.06. Delayed Data. As of Nov 17. +0.39 / +5.85%. Today’s Change. 4.54. Today ||| 52-Week Range. 16.75.2 days ago · RXRX has an Altman Z-Score of 1.55 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy. Detailed statistics for Recursion Pharmaceuticals, Inc. (RXRX) stock, including valuation metrics, financial numbers, share information and more.
NVIDIA Corporation Common Stock. $416.10 +5.93 +1.45%. ARM. Arm Holdings plc American Depositary Shares. $51.32 -0.84 -1.61%. Find the latest analyst research for Recursion Pharmaceuticals, Inc ...
In this article, we answer “what is sales forecasting?” by breaking down its objectives, owners, methods, and best practices. Sales | What is REVIEWED BY: Jess Pingrey Jess served on the founding team of a successful B2B startup and has use...
According to the issued ratings of 2 analysts in the last year, the consensus rating for Xerox stock is Sell based on the current 2 sell ratings for XRX. The average twelve-month price prediction for Xerox is $14.67 with a high price target of $17.00 and a low price target of $12.00. Learn more on XRX's analyst rating history.JPMorgan Trims Price Target on Recursion Pharmaceuticals to $10 From $11, Maintains Neutral Rating. Nov. 13. MT. Needham Adjusts Recursion Pharmaceuticals Price Target to $15 From $17, Maintains Buy Rating. Nov. 10. MT. Recursion Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September …Recursion’s Q1 2023 earnings show revenue as small but growing fast, growing from $5.3 million to $12.1 million year on year. With a net-loss of $65 million, Recursion is still an unprofitable ...Nov 24, 2023 · The average twelve-month price prediction for Recursion Pharmaceuticals is $11.20 with a high price target of $15.00 and a low price target of $8.00. Learn more on RXRX's analyst rating history. Do Wall Street analysts like Recursion Pharmaceuticals more than its competitors? The 23andMe Holding Co. stock forecast for tomorrow is $ 0.786773, which would represent a -1.46% loss compared to the current price. In the next week, the price of ME is expected to decrease by -7.39% and hit $ 0.739421. As far as the long-term 23andMe Holding Co. stock forecast is concerned, here’s what our predictions are currently suggesting.
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools. Identify stocks that meet your criteria using seven unique stock screeners.NSD:RXRX Detailed Stock Analysis, Stock Price Forecast, Analyst Ratings, Financial Analysis, Stock News & Historic QuotesDec 1, 2023 · Company Summary. Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data ... Nowadays finding high-quality stock photos for personal or commercial use is very simple. You just need to search the photo using a few descriptive words and let Google do the rest of the work.Recursion Pharmaceuticals (NASDAQ: RXRX) stock popped in July, fueled by a game-changing development—a direct investment of $50 million from Nvidia. But, since that month’s peak, RXRX’s ...
Find the latest Earnings Report Date for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at ... Read our earnings report guide before you consider the forecast information when making ...JPMorgan Trims Price Target on Recursion Pharmaceuticals to $10 From $11, Maintains Neutral Rating. Nov. 13. MT. Needham Adjusts Recursion Pharmaceuticals Price Target to $15 From $17, Maintains Buy Rating. Nov. 10. MT. Recursion Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September …
NVIDIA Corporation Common Stock. $416.10 +5.93 +1.45%. ARM. Arm Holdings plc American Depositary Shares. $51.32 -0.84 -1.61%. Find the latest analyst research for Recursion Pharmaceuticals, Inc ...When planning outdoor activities or making travel arrangements, having access to accurate weather forecasts is crucial. One commonly used tool is the 7 day weather forecast, which provides an outlook for the upcoming week.Wall Street Analysts Forecast Growth. RXRX has been the topic of several research reports. Needham & Company LLC dropped their target price on Recursion …Oct 11, 2023 · On the bottom line, Recursion's net loss per share of $0.38 remained flat compared to the prior-year quarter. The company ended the period with $405.9 million in cash and equivalents, which does ... Current. -$0.35. 1 Month Ago. -$0.35. 3 Months Ago. -$0.32. Recursion Pharmaceuticals Inc. analyst estimates, including RXRX earnings per share estimates and analyst recommendations.Analyst Future Growth Forecasts. Earnings vs Savings Rate: RXRX is forecast to remain unprofitable over the next 3 years. Earnings vs Market: RXRX is …Recursion Pharmaceuticals (RXRX 7.88%) is a biotech that's riding a hype wave unlike any other. By staking its fame and investors' cash on its artificial intelligence (AI) platform for drug ...
NVIDIA Corporation Common Stock. $416.10 +5.93 +1.45%. ARM. Arm Holdings plc American Depositary Shares. $51.32 -0.84 -1.61%. Find the latest analyst research for Recursion Pharmaceuticals, Inc ...
Recursion Pharmaceuticals Inc Cl A (RXRX) $7.05 0.38 (5.70%) 16:00 EST RXRX Stock Quote Delayed 30 Minutes.
Ticker Symbol: RXRX: Exchange: NASDAQ: Fiscal Year: January - December: Reporting Currency: USD: IPO Price: $18.00: CIK Code: 0001601830: CUSIP Number: 75629V104 ...Based on short-term price targets offered by seven analysts, the average price target for Recursion Pharmaceuticals comes to $15.29. The forecasts range from a low of $9.00 to a high of $33.00 ...The consensus price target of analysts on Wall Street is $16.00, which implies an increase of 65.31% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $9.00 and $35.00 respectively. As a result, RXRX is trading at a discount of -530.63% off the target high and -62.16% off the low.The consensus price target of analysts on Wall Street is $16.00, which implies an increase of 65.31% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $9.00 and $35.00 respectively. As a result, RXRX is trading at a discount of -530.63% off the target high and -62.16% off the low.Stock analysis for Recursion Pharmaceuticals Inc (RXRX:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.beststocks.com8 нояб. 2023 г. ... RXRX Stock Recursion Pharmaceuticals top stocks to buy in August ... Unity Stock New CEO Prioritizes Investors Over Stock Price. Jose Najarro ...Sep 22, 2023 · According to data from CNN Money, the company had 7 analysts offering 12-month price forecasts. The median target price was $14.00, with a high estimate of $35.00 and a low estimate of $9.00. The consensus among the 7 polled investment analysts was to hold the stock of Recursion Pharmaceuticals Inc. This rating had remained steady since ... Find the latest Recursion Pharmaceuticals, Inc. RXRX analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports. Date Range.Sep 22, 2023 · According to data from CNN Money, the company had 7 analysts offering 12-month price forecasts. The median target price was $14.00, with a high estimate of $35.00 and a low estimate of $9.00. The consensus among the 7 polled investment analysts was to hold the stock of Recursion Pharmaceuticals Inc. This rating had remained steady since ...
The company's shares are currently changing hands for $7.07 apiece, but the consensus one-year target for the stock is $15.57, which implies that it could rise by about 120% over the next 12 months.People use statistics daily for weather forecasts, predicting disease, preparing for emergencies, medical research, political campaigns, tracking sales, genetics, insurance, the stock market and quality testing.According to the National Snow & Ice Data Center, blizzard prediction relies on modeling weather systems, as well as predicting temperatures. The heavy snowfall that blizzards create can be hard to predict in advance.beststocks.comInstagram:https://instagram. online finance courses for beginnersamazon and doordashark etf holdingshow to buy altcoins The stock with a short interest of ~14% has added more than 92% this month, including a ~13% rise on Tuesday when ~7.2M company shares changed hands compared to the 65-day average of ~1.5M. how to buy crypto with cash appfidelity crypto trading May 18, 2023 · "Over the next 10 years, AI could increase productivity by 1.5% per year. And that could increase S&P500 profits by 30% or more over the next decade," Goldman Sach's senior strategist Ben Snider ... 2 days ago · RXRX has an Altman Z-Score of 1.55 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy. Detailed statistics for Recursion Pharmaceuticals, Inc. (RXRX) stock, including valuation metrics, financial numbers, share information and more. nasdaq cprx Jul 21, 2023 · NASDAQ: RXRX Recursion Pharmaceuticals. Market Cap. $2B. Today's Change (7.88%) $0.54. Current Price. $7.39. ... Recursion's stock is up 73% this year, and while it doesn't have any recurring ... Find the latest RxSight, Inc. (RXST) stock quote, history, news and other vital information to help you with your stock trading and investing.